Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as "ATLATL"), global innovation platform for life science research and development, announced that the companies have entered into a Memorandum of Understanding (MoU) on an open innovation program to accelerate early-stage biotech innovation in Asia-Pacific.

Through this partnership, Samsung Bioepis aims to leverage ATLATL’s innovative R&D network and expertise in the Asia-Pacific biotech sector to identify and support promising early-stage biotech companies and breakthrough technologies.

“External innovation is becoming increasingly important in drug development—not only to identify and foster promising early-stage technologies and companies, but also to cultivate a broader innovation ecosystem,” said Min Jeong Seo, Vice President and Leader of Open Innovation Team, at Samsung Bioepis. “By leveraging ATLATL’s extensive network and ecosystem as one of the largest biotech incubation centers in the Asia-Pacific region, we believe strategic partnerships can help accelerate the translation of promising science into meaningful medicines for patients.”

“ATLATL connects early-stage science with the infrastructure and expertise needed for real-world translation,” said Dr. PC Zhu, founder and CEO of ATLATL. “Through our integrated R&D ecosystem across Asia-Pacific, and in collaboration with Samsung Bioepis, we aim to accelerate the development of high-potential technologies and bring impactful therapies to patients more efficiently.”

As part of this collaboration, Samsung Bioepis plans to launch the Innovation Prize, an open innovation program in partnership with ATLATL. Through this initiative, selected early-stage biotech companies will have the opportunity to reside at ATLATL’s incubation center with access to world-class resources, infrastructure, and expertise to accelerate their growth and development.